John Turman Fleming Sells 500 Shares of USANA Health Sciences, Inc. (NYSE:USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director John Turman Fleming sold 500 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $33.30, for a total value of $16,650.00. Following the sale, the director now owns 4,026 shares in the company, valued at approximately $134,065.80. This trade represents a 11.05 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

USANA Health Sciences Stock Down 6.5 %

Shares of USANA Health Sciences stock opened at $30.38 on Friday. USANA Health Sciences, Inc. has a fifty-two week low of $27.71 and a fifty-two week high of $50.32. The firm has a market cap of $579.12 million, a PE ratio of 10.74, a P/E/G ratio of 0.93 and a beta of 0.98. The business’s fifty day moving average is $32.79 and its two-hundred day moving average is $36.05.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.15. The business had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. Equities research analysts anticipate that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in USNA. R Squared Ltd purchased a new position in shares of USANA Health Sciences in the 4th quarter worth $28,000. Safe Harbor Fiduciary LLC purchased a new position in shares of USANA Health Sciences in the 3rd quarter worth $30,000. KBC Group NV raised its position in shares of USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after buying an additional 519 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of USANA Health Sciences in the 4th quarter worth $83,000. Finally, Quantbot Technologies LP purchased a new position in shares of USANA Health Sciences in the 4th quarter worth $132,000. 54.25% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

USNA has been the topic of a number of analyst reports. Sidoti cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. StockNews.com lowered USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Finally, DA Davidson reduced their price target on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.